Putting chirality to work: The strategy of chiral switches

被引：498

作者：

Agranat, I

Caner, H

Caldwell, A

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, London SW7 2AZ, England

[2] Hebrew Univ Jerusalem, Dept Organ Chem, IL-91904 Jerusalem, Israel

来源：

NATURE REVIEWS DRUG DISCOVERY | 2002年 / 1卷 / 10期

关键词：

D O I：

10.1038/nrd915

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixtures that dominated up to ten years ago. Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates. Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.

引用

页码：753 / 768

页数：16

共 134 条

[51]

GAL J, 1997, FED REGISTER, V62, P2167

[52]

Gardner M, 1990, AMBIDEXTROUS UNIVERS, V3rd

[53]

GRAHAM D, 1998, Patent No. 5776765

[54]

Graul A., 1999, Drugs of the Future, V24, P1178, DOI 10.1358/dof.1999.024.11.559951

[55]

GRAY NM, 1994, Patent No. 9401111

[56]

GRAY NM, 1994, Patent No. 939169967

[57]

GRAY NM, 1994, Patent No. 9401112

[58]

GRAY NM, 1994, Patent No. 939181553

[59]

Gristwood R W, 1999, Expert Opin Investig Drugs, V8, P861, DOI 10.1517/13543784.8.6.861

[60] Cardiac and CNS toxicity of levobupivacaine - Strength of evidence for advantage over bupivacaine [J].

Gristwood, RW .

DRUG SAFETY, 2002, 25 (03) :153-163

← 1 2 3 4 5 6 7 8 9 10 →